DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus

Robert A. Rasmussen, R. Hofmann-Lehmann, D. C. Montefiori, P. L. Li, V. Liska, J. Vlasak, T. W. Baba, J. E. Schmitz, M. J. Kuroda, H. L. Robinson, H. M. McClure, S. Lu, S. L. Hu, T. A. Rizvi, R. M. Ruprecht

Research output: Contribution to journalArticlepeer-review

33 Citations (Scopus)

Abstract

Newborn macaques were vaccinated against a chimeric simian human immunodeficiency (SHIV) virus, SHIV-vpu+, by DNA priming and boosting with homologous HIV-1 gp160. Following SHIV-vpu+ challenge, containment of infection was observed in 4 of 15 animals given DNA priming/protein boost vaccination and in three of four animals given gp160 boosts only. Rechallenge with homologous virus of six animals that contained the first challenge virus resulted in rapid viral clearance or low viral loads. Upon additional rechallenge with heterologous, pathogenic SHIV89.6P, four of these six animals maintained normal CD4+ T-cell counts with no or limited SHIV89.6P infection. Our data suggest that humoral and cellular immune mechanisms may have contributed to the containment of SHIV89.6P; however, viral interference with SHIV-vpu+ could also have played a role. Our results indicate that immunogenicity and efficacy of candidate AIDS vaccines are not affected when vaccination is initiated during infancy as compared with later in life.

Original languageEnglish
Pages (from-to)40-60
Number of pages21
JournalJournal of medical primatology
Volume31
Issue number1
DOIs
Publication statusPublished - 2002
Externally publishedYes

Keywords

  • Cytolytic T lymphocytes
  • Neutralizing antibodies
  • gp160

ASJC Scopus subject areas

  • Animal Science and Zoology
  • General Veterinary

Fingerprint

Dive into the research topics of 'DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus'. Together they form a unique fingerprint.

Cite this